Advisory Group's work on handling Genetic Sequence Data under the PIP Framework
PIP Framework section 5.2.4 requests the Director-General to consult with the PIP Advisory Group on the best process for further discussion and resolution of issues related to the handling of the genetic sequence data (GSD) of influenza viruses with pandemic potential, under the Framework.
The PIP Advisory Group commenced its work on this issue in June 2013. Since then, it has conducted technical work, in consultation with PIP stakeholders, in order to understand how GSD is developed, shared and used with a view to proposing to the Director-General, options for handling GSD under the Framework that are consistent with and reflect the Framework’s objectives.
Technical Working Group (TWG) on sharing influenza GSD
Established in April 2015 by the PIP AG, the Technical Working Group (TWG) was requested to identify the optimal characteristics and best practices of a GSD sharing system that best meets the objectives of the Framework. The document submitted by the TWG to the PIP Advisory Group in May 2016 was developed from July 2015-May 2016 and included consultation with Member States and stakeholders.
TWG Submission to the Advisory Group (22 June 2016)
- Optimal characteristics of an influenza genetic sequence data sharing system under the PIP Framework
This version also includes a cover letter from the TWG Chair to the PIP Advisory Group, which provides context and clarifications on the TWG process.
Public consultation
Comments received on the draft document “Optimal characteristics of an influenza genetic sequence data sharing system under the PIP Framework"
In November 2015, the Chair of the PIP Framework Advisory Group’s Technical Working Group on the sharing of influenza genetic sequence data (the TWG) shared a draft document entitled "Optimal characteristics of an influenza genetic sequence data sharing system under the PIP Framework” with stakeholders.
All submissions that have been received to date by the Secretariat are posted below.
- Australia's comments
- COMPARE consortium's comments
- COMPARE consortium and Global Microbial Identifier (GMI) initiative's comments
- Czech Republic's comments
- ELIXIR's comments
- Federal Republic of Germany's comments
- GISAID's comments
- International Nucleotide Sequence Databases' comments
- IRD's comments
- New Zealand's comments
- National Influenza Center, Korea's comments
- OFFLU's comments
- OFFLU's comments with additional remarks
- Third World Network's comments
TWG Meeting Reports
TWG Members
TWG Terms of Reference
Monitoring the use of Influenza GSD in end-products
This document identifies different options for monitoring the use of GSD in the development of influenza products, such as vaccines, antivirals and diagnostics. This document was developed in consultation with Member States and stakeholders.
- Options to monitor the use of genetic sequence data from influenza viruses with human pandemic potential (IVPP GSD) in end-products, REVISED 6 May 2016
- Draft Options to monitor the use of genetic sequence data from influenza viruses with human pandemic potential (IVPP GSD) in end-products (September 2015)
- Federal Republic of Germany’s comments on the Options paper
- GISAID Initiative’s comments on the Options paper
- Third World Network's comments on the Options paper
Technical Expert Working Group (TEWG) on GSD
In October 2013, the PIP AG established a Technical Expert Working Group (TEWG) to assess the scientific, technical, operational and intellectual property implications of using GSD to develop vaccines, diagnostic and pharmaceutical products.
TEWG Reports
- TEWG Final Report to the PIP Advisory Group, REVISED 10 October 2014
- TEWG Final Report to the PIP Advisory Group, 15 May 2014
This document was revised and reissued on 10 October 2014.
TEWG Members
TEWG Terms of Reference
WHO Survey on the sharing of GSD